Helping projects
change the future
APPLY NOW

News

Primer Capital to partner with Startup Rally 2020

1 April 2020

The application for participation in the Startup-Rally 2020 for pharmaceutical and healthcare projects is open.

Primer Capital to partner with Startup Rally 2020

The application for participation in the Startup-Rally 2020 for pharmaceutical and healthcare projects is open.
 

Primer Capital CEO speaking at the OpenTalks.AI

25 February 2020

February 21, Anton Lavrentyev, the CEO of Primer Capital participated in a panel discussion on Investing in AI within the OpenTalks.AI conference.

Primer Capital CEO speaking at the OpenTalks.AI

February 21, Anton Lavrentyev, the CEO of Primer Capital participated in a panel discussion on Investing in AI within the OpenTalks.AI conference.
 

6 lifehacks on how to work with a start-up

29 January 2020

Read another blog piece by Anton Lavrentev, Primer Capital CEO for VC.ro on 6 lifehacks on how to work with start-ups.

6 lifehacks on how to work with a start-up

Read another blog piece by Anton Lavrentev, Primer Capital CEO for VC.ro on 6 lifehacks on how to work with start-ups.
 

Primer Capital Founders featured in Forbes

3 December 2019

Primer Capital founders, Dmitry Sharov and Timur Avdeenko shared the story of the fund in a feature story by Forbes Russia.

Primer Capital Founders featured in Forbes

Primer Capital founders, Dmitry Sharov and Timur Avdeenko shared the story of the fund in a feature story by Forbes Russia.
 

Primer Capital at the III International Medical Investment Forum

28 November 2019

Primer Capital COO Elizaveta Rozhdestvenskaya spoke at the round table on Investing in Science during the III International Medical Investment Forum 2019.

Primer Capital at the III International Medical Investment Forum

Primer Capital COO Elizaveta Rozhdestvenskaya spoke at the round table on Investing in Science during the III International Medical Investment Forum 2019.
 

Primer Capital's porfolio project, raises €7M in addtion to its Series B

6 November 2019

Acticor Biotech, Primer Capital's portfolio unit, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million.

Primer Capital's porfolio project, raises €7M in addtion to its Series B

Acticor Biotech, Primer Capital's portfolio unit, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million.
 

With luck it takes at least seven years for the product to enter the market

23 October 2019

In her interview for Rusbase Primer Capital COO Elizaveta Rozhdenstvenskaya shared her thoughts on the pharma and biotech startups and the overall venture market trends.

With luck it takes at least seven years for the product to enter the market

In her interview for Rusbase Primer Capital COO Elizaveta Rozhdenstvenskaya shared her thoughts on the pharma and biotech startups and the overall venture market trends.
 

Primer Capital CEO speaking at the round table by the Analytics Center for the Government of the Russian Federation

30 September 2019

Anton Lavrentev took part in the discussion on the “Direct and Venture Investment Funds as a Key Tool in Financing Digital Economy” held by the Analytics Center for the Government of the Russian Federation.

Primer Capital CEO speaking at the round table by the Analytics Center for the Government of the Russian Federation

Anton Lavrentev took part in the discussion on the “Direct and Venture Investment Funds as a Key Tool in Financing Digital Economy” held by the Analytics Center for the Government of the Russian Federation.
 

Investing in the development of a drug that eliminates the consequences of neurodegenerative diseases

11 September 2019

Primer Capital Venture Fund invested in a US-based company. The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases. The portfolio of Primer Capital now includes 11 projects from Russia, USA, Israel and France.

Investing in the development of a drug that eliminates the consequences of neurodegenerative diseases

Primer Capital Venture Fund invested in a US-based company. The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases. The portfolio of Primer Capital now includes 11 projects from Russia, USA, Israel and France.
 

How can a venture fund assist in drug development?

20 August 2019

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.

How can a venture fund assist in drug development?

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.

Записи 1 - 10 of 58
First | Prev. | 1 2 3 4 5 | Next | Last